Out to ‘re­think the drug de­sign process,’ AI star Daphne Koller is cre­at­ing a new ma­chine learn­ing ven­ture at in­sitro with some heavy­weight back­ers

Daphne Koller has been busy.

Just two months since the high pro­file AI ex­pert ex­it­ed Google’s an­ti-ag­ing biotech Cal­i­co Labs, where she was chief com­put­ing of­fi­cer, Koller has gath­ered a group of mar­quee in­vestors to back a tech up­start — in­sitro — with plans to de­vel­op a ma­chine learn­ing plat­form equipped with cus­tom-built datasets to cre­ate a new and far more ef­fi­cient ap­proach to drug dis­cov­ery and de­vel­op­ment.

AI cir­cles have been buzzing with spec­u­la­tion and queries about what the for­mer Stan­ford pro­fes­sor planned to do af­ter ex­it­ing Cal­i­co, where she had been de­vel­op­ing com­pu­ta­tion­al meth­ods for an­a­lyz­ing bi­o­log­i­cal da­ta sets. She an­swered at least some of those ques­tions with a blog post late Tues­day that spelled out her com­mit­ment to “in­vest heav­i­ly” in cre­at­ing new datasets that can ac­cel­er­ate the use of ma­chine learn­ing in bio­phar­ma.

Koller has some high rollers back­ing the start­up, in­clud­ing some ven­ture groups well known for block­buster fundrais­ing and a yen for trans­for­ma­tion­al ven­tures. They are: Arch Ven­ture Part­ners, Fore­site Cap­i­tal, a16z, GV (for­mer­ly Google Ven­tures) and Third Rock.

In­sitro, she says, will “col­lect and use a range of very large da­ta sets to train ML mod­els that will help ad­dress key prob­lems in the drug dis­cov­ery and de­vel­op­ment process. To en­able the ma­chine learn­ing, we will use high-qual­i­ty da­ta that has al­ready been col­lect­ed, but we will al­so in­vest heav­i­ly in the cre­ation of our own datasets us­ing high through­put ex­per­i­men­tal ap­proach­es, datasets that are de­signed ex­plic­it­ly with ma­chine learn­ing in mind from the very start. The ML mod­els that are de­vel­oped will then help guide sub­se­quent ex­per­i­ments, pro­vid­ing a tight, closed loop in­te­gra­tion of in sil­i­co and in vit­ro meth­ods (an in­sitro par­a­digm).”

Ac­cord­ing to Koller, the low hang­ing fruit in drug dis­cov­ery has been picked. Reach­ing high­er, go­ing for much bet­ter drugs, will re­quire “a dif­fer­ent ap­proach to drug de­vel­op­ment.” Spend­ing bil­lions to de­vel­op new drugs — and then pass­ing the cost to pa­tients — is not sus­tain­able.

In launch­ing in­sitro with a group of hy­per con­nect­ed back­ers, Koller is in­stant­ly mak­ing her­self a top play­er in a field that has Big Phar­ma’s rapt at­ten­tion. Stream­lin­ing R&D and im­prov­ing the odds of suc­cess find­ing high im­pact ther­a­pies are con­sid­ered keys to longterm prof­itabil­i­ty. But now the fo­cus is on which out­fits can ac­tu­al­ly de­liv­er.

There will be plen­ty of peo­ple watch­ing to see if Koller and the team she’s now re­cruit­ing can per­form. And she knows it won’t be easy. She writes:

There is a lot of hype to­day around ma­chine learn­ing, with hy­per­bol­ic promis­es that it will mag­i­cal­ly solve all of hu­mankind’s prob­lems (and dire warn­ings that it will lead to the de­struc­tion of hu­mankind). We at in­sitro don’t ex­pect ML to be the so­lu­tion to all of the prob­lems in drug de­vel­op­ment, nor to be the mag­ic bul­let that helps find a treat­ment for every dis­ease. How­ev­er, we do be­lieve that the time is right to re­think the drug de­sign process us­ing a dif­fer­ent and more mod­ern toolk­it, in the hope that a new par­a­digm may help us cure more peo­ple, soon­er, and at a much low­er cost.

I’d queried Koller re­cent­ly af­ter hear­ing word about in­sitro. For now, she tells me in a mes­sage, her blog post goes about as deep in­to this as she wants to go right now. But more is com­ing.


Im­age: Daphne Koller. STAN­FORD

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.